New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

Teva Pharmaceutical Industries will pay $450 to settle the Department of Justice's investigation into allegations of price fixing and misuse of funds for kickbacks. Other pharmaceutical news reports ...

Zealand Pharma is working on the next-gen weight-loss treatment. Its Petrelintide showed promising results in a Phase 1b ...

Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...